ACVR2A and familial pancreatic carcinoma: However, the fact that the survival was not improved may not be entirely due to the absence of beneficial effects of ACVR2 signaling blocking in tissues other than skeletal muscle, especially since, as mentioned above, systemic blockade of these ligands did not ameliorate survival even in a tumor-model with high levels of activin A, unlike when pancreatic cancer cells expressing low levels of activin A were implanted [146].